脑肌醇作为淀粉样蛋白相关病理的潜在标志物:一项纵向研究
本研究基于瑞典BioFINDER队列,对294名无痴呆参与者(认知健康、主观认知下降、轻度认知障碍)进行多次质子磁共振波谱(MRS)采集,共670份谱图,分析MRS代谢物纵向变化与β-淀粉样蛋白(Aβ)病理及认知下降的关系。结果显示,Aβ阳性组中肌醇/肌酸(mI/Cr)年变化率为+1.9%,N-乙酰天冬氨酸/肌醇(NAA/mI)为-2.0%,且基线NAA/mI低的Aβ阳性个体认知下降更快。结论认为MRS可能是Aβ相关过程的非侵入性标志物。
要点
- Aβ阳性个体中mI/Cr每年上升1.9%,NAA/mI每年下降2.0%。
- 轻度认知障碍Aβ阳性组MRS变化最陡:mI/Cr +2.93%/年(p=0.07),NAA/mI -3.55%/年(p<0.01)。
- Aβ阳性个体中基线NAA/mI低者认知下降速率显著更高。
核心结论
- mI/Cr和NAA/mI的纵向变化与潜在淀粉样蛋白病理相关,MRS可能是Aβ相关过程的非侵入性标志物。
- 在Aβ阳性个体中,基线NAA/mI可能预测未来认知下降速率。
研究设计与样本
- 纵向多时间点研究,为瑞典BioFINDER的子集,纳入认知健康、主观认知下降和轻度认知障碍参与者。
- 共294名参与者,从后扣带/楔前叶采集670份MRS谱图,使用混合效应模型分析。
主要发现
- 基线MRS代谢物在Aβ阳性和阴性个体间相似。
- Aβ阳性组mI/Cr估计年变化率为+1.9%,NAA/mI为-2.0%。
- Aβ阴性组mI/Cr和NAA/mI年变化分别为-0.05%和+1.2%,但跨时间点不显著。
- 轻度认知障碍Aβ阳性组MRS变化最陡:mI/Cr +2.93%/年(p=0.07),NAA/mI -3.55%/年(p<0.01)。
- 整个队列中,基线NAA/mI低的Aβ阳性个体认知下降速率显著高于基线NAA/mI高的Aβ阳性个体。
关键数值与推荐
- Aβ阳性组mI/Cr年变化+1.9%,NAA/mI年变化-2.0%。
- Aβ阴性组mI/Cr年变化-0.05%,NAA/mI年变化+1.2%,跨时间点不显著。
- 轻度认知障碍Aβ阳性组mI/Cr年变化+2.93%(p=0.07),NAA/mI年变化-3.55%(p<0.01)。
临床怎么用
- MRS可作为无创监测Aβ相关病理进展的潜在工具。
- 对Aβ阳性个体,基线NAA/mI可能帮助预测未来认知下降速率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the association between longitudinal changes in proton magnetic resonance spectroscopy (MRS) metabolites and amyloid pathology in individuals without dementia, and to explore the relationship between MRS and cognitive decline. METHODS: In this longitudinal multiple time point study (a subset of the Swedish BioFINDER), we included cognitively healthy participants, individuals with subjective cognitive decline, and individuals with mild cognitive impairment. MRS was acquired serially in 294 participants (670 individual spectra) from the posterior cingulate/precuneus. Using mixed-effects models, we assessed the association between MRS and baseline β-amyloid (Aβ), and between MRS and the longitudinal Mini-Mental State Examination, accounting for APOE, age, and sex. RESULTS: While baseline MRS metabolites were similar in Aβ positive (Aβ+) and negative (Aβ-) individuals, in the Aβ+ group, the estimated rate of change was +1.9%/y for myo-inositol (mI)/creatine (Cr) and -2.0%/y for N-acetylaspartate (NAA)/mI. In the Aβ- group, mI/Cr and NAA/mI yearly change was -0.05% and +1.2%; however, this was not significant across time points. The mild cognitive impairment Aβ+ group showed the steepest MRS changes, with an estimated rate of +2.93%/y (p = 0.07) for mI/Cr and -3.55%/y (p < 0.01) for NAA/mI. Furthermore, in the entire cohort, we found that Aβ+ individuals with low baseline NAA/mI had a significantly higher rate of cognitive decline than Aβ+ individuals with high baseline NAA/mI. CONCLUSION: We demonstrate that the longitudinal change in mI/Cr and NAA/mI is associated with underlying amyloid pathology. MRS may be a useful noninvasive marker of Aβ-related processes over time. In addition, we show that in Aβ+ individuals, baseline NAA/mI may predict the rate of future cognitive decline.
引用
- Voevodskaya O, Poulakis K, Sundgren P, et al. Brain myoinositol as a potential marker of amyloid-related pathology: A longitudinal study. Neurology. 2019. PMID: 30610093. doi:10.1212/WNL.0000000000006852
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。